Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys Acquires Serotec for $35.3M, Expanding Research Antibody Line

NEW YORK, Jan. 12 (GenomeWeb News) - Antibody company MorphoSys has acquired privately held Serotec, an Oxford, England-based supplier of antibodies for research applications, the companies said today.

 

Munich, Germany-based MorphoSys will pay a total of £20 million ($35.3 million) for Serotec, with £14 million of that amount paid in cash and the remainder paid through the issuance of 208,560 new shares, the companies said.

 

Serotec will become a subsidiary of MorphoSys and will continue to sell its products to the research market, according to the statement. The acquisition, which is intended to expand the company's research antibody business, will give MorphoSys a distribution network in the United States, the United Kingdom, France, and Scandinavia, the companies said.

 

MorphoSys' January 2005 acquisition of Biogenesis was also intended to expand its research antibody business.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.